Metabolic profiling of the anti-tumor drug regorafenib in mice
Wang, Yi-Kun1,2; Xiao, Xue-Rong1; Xu, Kang-Ping3; Li, Fei1
AbstractRegorafenib is a novel tyrosine kinase inhibitor, which has been approved by the United States Food and DrugAdministration for the treatment of various tumors. The purpose of the present study was to describe the metabolic map of regorafenib, and investigate its effect on liver function. Mass spectrometry-based metabolomics approach integrated with multiple mass defect filter was used to determine the metabolites of regorafenib in vitro incubation mixtures (human liver microsomes and mouse liver microsomes), serum, urine and feces samples from mice treated with 80 mg/kg regorafenib. Eleven metabolites including four novel metabolites were identified in the present investigation. As halogen substituted drug, reductive defluorination and oxidative dechlorination metabolites of regorafenib were firstly report in present study. By screening using recombinant cytochrome P450 s (CYPs), CYP3A4 was found to be the principal isoforms involved in regorafenib metabolism. The predication with a molecular docking model confirmed that regorafenib had potential to interact with the active sites of CYP3A4, CYP3A5 and CYP2D6. Serum chemistry analysis revealed no evidence of hepatic damage from regorafenib exposure. This study provided a global view of regorafenib metabolism and its potential side-effects. (C) 2018 Elsevier B.V. All rights reserved.
KeywordRegorafenib Metabolomics Multiple mass defect filters Molecular docking
WOS Research AreaChemistry ; Pharmacology & Pharmacy
WOS SubjectChemistry, Analytical ; Pharmacology & Pharmacy
WOS IDWOS:000442699900058
Citation statistics
Document Type期刊论文
Corresponding AuthorLi, Fei
Affiliation1.Chinese Acad Sci, Kunming Inst Bot, States Key Lab Phytochem & Plant Resources West C, Kunming 650201, Yunnan, Peoples R China
2.Univ Chinese Acad Sci, Beijing 100049, Peoples R China
3.Cent S Univ, Xiangya Sch Pharmaceut Sci, Changsha 410013, Hunan, Peoples R China
Recommended Citation
GB/T 7714
Wang, Yi-Kun,Xiao, Xue-Rong,Xu, Kang-Ping,et al. Metabolic profiling of the anti-tumor drug regorafenib in mice[J]. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS,2018,159:524-535.
APA Wang, Yi-Kun,Xiao, Xue-Rong,Xu, Kang-Ping,&Li, Fei.(2018).Metabolic profiling of the anti-tumor drug regorafenib in mice.JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS,159,524-535.
MLA Wang, Yi-Kun,et al."Metabolic profiling of the anti-tumor drug regorafenib in mice".JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS 159(2018):524-535.
Files in This Item:
There are no files associated with this item.
Related Services
Recommend this item
Usage statistics
Export to Endnote
Google Scholar
Similar articles in Google Scholar
[Wang, Yi-Kun]'s Articles
[Xiao, Xue-Rong]'s Articles
[Xu, Kang-Ping]'s Articles
Baidu academic
Similar articles in Baidu academic
[Wang, Yi-Kun]'s Articles
[Xiao, Xue-Rong]'s Articles
[Xu, Kang-Ping]'s Articles
Bing Scholar
Similar articles in Bing Scholar
[Wang, Yi-Kun]'s Articles
[Xiao, Xue-Rong]'s Articles
[Xu, Kang-Ping]'s Articles
Terms of Use
No data!
Social Bookmark/Share
All comments (0)
No comment.

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.